Alan Lamont

4.2k total citations · 1 hit paper
54 papers, 3.2k citations indexed

About

Alan Lamont is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Alan Lamont has authored 54 papers receiving a total of 3.2k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Immunology, 17 papers in Oncology and 11 papers in Molecular Biology. Recurrent topics in Alan Lamont's work include Immunotherapy and Immune Responses (11 papers), Immune Cell Function and Interaction (11 papers) and T-cell and B-cell Immunology (11 papers). Alan Lamont is often cited by papers focused on Immunotherapy and Immune Responses (11 papers), Immune Cell Function and Interaction (11 papers) and T-cell and B-cell Immunology (11 papers). Alan Lamont collaborates with scholars based in United Kingdom, United States and Germany. Alan Lamont's co-authors include Mahesh Parmar, Gunnar B. Kristensen, Gordon C. Jayson, C. Tropé, Jonathan A. Ledermann, Sarah Wheeler, Valter Torri, Irene Floriani, Delaloye Jf and Andreas du Bois and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and The Journal of Immunology.

In The Last Decade

Alan Lamont

53 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial

2003 885 citations Mahesh Parmar, Gunnar B. Kristensen et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alan Lamont United Kingdom	27	1.1k	1.1k	822	765	595	54	3.2k
Joseph P. Connor United States	27	814 0.7×	603 0.6×	688 0.8×	889 1.2×	394 0.7×	88	2.7k
Antonella Ravaggi Italy	34	833 0.8×	777 0.7×	967 1.2×	783 1.0×	284 0.5×	104	3.3k
C. H. Buckley United Kingdom	34	541 0.5×	1.1k 1.0×	588 0.7×	474 0.6×	526 0.9×	106	3.1k
Mack N. Barnes United States	33	1.3k 1.2×	833 0.8×	262 0.3×	1.5k 2.0×	346 0.6×	80	3.3k
Jonathan M. Niloff United States	24	860 0.8×	2.9k 2.7×	930 1.1×	1.2k 1.5×	994 1.7×	47	4.8k
Kian Behbakht United States	34	1.2k 1.1×	1.1k 1.0×	319 0.4×	1.7k 2.2×	303 0.5×	127	3.9k
Madhuri Koti Canada	31	949 0.9×	1.1k 1.0×	1.6k 2.0×	1.0k 1.3×	280 0.5×	82	3.3k
Malcolm Adams United Kingdom	21	500 0.5×	452 0.4×	1.1k 1.3×	1.0k 1.4×	375 0.6×	47	2.7k
Sarah Wheeler United States	25	977 0.9×	738 0.7×	241 0.3×	935 1.2×	553 0.9×	98	3.4k
Elke A. Jarboe United States	27	537 0.5×	1.3k 1.2×	235 0.3×	635 0.8×	424 0.7×	70	2.5k

Countries citing papers authored by Alan Lamont

Since Specialization

Citations

This map shows the geographic impact of Alan Lamont's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Lamont with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Lamont more than expected).

Fields of papers citing papers by Alan Lamont

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Lamont. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Lamont. The network helps show where Alan Lamont may publish in the future.

Co-authorship network of co-authors of Alan Lamont

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Lamont. A scholar is included among the top collaborators of Alan Lamont based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Lamont. Alan Lamont is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Banerjee, Susana, James Paul, Christopher J.M. Williams, et al.. (2012). A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. Annals of Oncology. 24(3). 679–687. 31 indexed citations

Rustin, Gordon, Clare Griffin, David Guthrie, et al.. (2010). Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. The Lancet. 376(9747). 1155–1163. 355 indexed citations

Colazo, M.G., Alan Lamont, John P. Kastelic, et al.. (2009). The effect of porcine luteinizing hormone in the synchronization of ovulation and corpus luteum development in nonlactating cows. Theriogenology. 72(1). 120–128. 14 indexed citations

Knight, Louise A., Federica Di Nicolantonio, Pauline A. Whitehouse, et al.. (2006). The effect of imatinib mesylate (Glivec) on human tumor-derived cells. Anti-Cancer Drugs. 17(6). 649–655. 13 indexed citations

Sharma, Sanjay, Michael H. Neale, Federica Di Nicolantonio, et al.. (2003). Outcome of ATP-based tumor chemosensitivity assay directed chemotherapy in heavily pre-treated recurrent ovarian carcinoma. BMC Cancer. 3(1). 19–19. 56 indexed citations

Shepherd, Frances A., Giuseppe Giaccone, Lesley Seymour, et al.. (2002). Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Marimastat After Response to First-Line Chemotherapy in Patients With Small-Cell Lung Cancer: A Trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer. Journal of Clinical Oncology. 20(22). 4434–4439. 192 indexed citations

Rusznák, C., Raymond J. Sapsford, J.L. Devalia, et al.. (2001). Interaction of cigarette smoke and house dust mite allergens on inflammatory mediator release from primary cultures of human bronchial epithelial cells. Clinical & Experimental Allergy. 31(2). 226–238. 34 indexed citations

Neale, Michael H., Nyree Myatt, P C Weaver, et al.. (2001). Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma. Melanoma Research. 11(6). 601–609. 35 indexed citations

Francis, James N., et al.. (2000). The route of administration of an immunodominant peptide derived from heat‐shock protein 65 dramatically affects disease outcome in pristane‐induced arthritis. Immunology. 99(3). 338–344. 11 indexed citations

10.

Elson, C. J., John Kirwan, J. S. Hill Gaston, et al.. (2000). Relationship between disease severity and responses by blood mononuclear cells from patients with rheumatoid arthritis to human heat‐shock protein 60. Immunology. 99(2). 208–214. 38 indexed citations

11.

Souhami, R L, SG Spiro, R.M. Rudd, et al.. (1997). Five-Day Oral Etoposide2 Treatment for Advanced Small-Cell Lung Cancer: Randomized Comparison With Intravenous Chemotherapy. JNCI Journal of the National Cancer Institute. 89(8). 577–580. 143 indexed citations

12.

Lamont, Alan, et al.. (1996). IL-12: a key cytokine in immune regulation. Immunology Today. 17(5). 214–217. 185 indexed citations

13.

Macbeth, Fergus, T. E. Wheldon, D.J. Girling, et al.. (1996). Radiation myelopathy: Estimates of risk in 1048 patients in three randomized trials of palliative radiotherapy for non-small cell lung cancer. Clinical Oncology. 8(3). 176–181. 65 indexed citations

14.

Lamont, Alan. (1994). Are we closer to selective immunotherapy for autoimmune diseases?. Immunology Today. 15(2). 45–47. 6 indexed citations

15.

Rustin, Gordon, Michael R.L. Stratford, Alan Lamont, et al.. (1992). Phase I study of intravenous 4-hydroxyanisole. European Journal of Cancer. 28(8-9). 1362–1364. 18 indexed citations

16.

Roudier, Jean, Alessandro Sette, Alan Lamont, et al.. (1991). Tolerance to a self peptide from the third hypervariable region of the E chain. Implications for molecular mimicry models of autoimmune disease. European Journal of Immunology. 21(9). 2063–2067. 18 indexed citations

17.

Lamont, Alan, A Sette, Robert S. Fujinami, et al.. (1990). Inhibition of experimental autoimmune encephalomyelitis induction in SJL/J mice by using a peptide with high affinity for IAs molecules.. The Journal of Immunology. 145(6). 1687–1693. 97 indexed citations

18.

Lamont, Alan, Alessandro Sette, & Howard M. Grey. (1990). Inhibition of Antigen PresentationIn VitroandIn Vivoby MHC Antagonist Peptides. International Reviews of Immunology. 6(1). 49–59. 6 indexed citations

19.

Grey, Howard M., Alessandro Sette, & Alan Lamont. (1989). Biologic significance and therapeutic implications of antigen/MHC interactions. Clinical Immunology and Immunopathology. 53(2). S47–S52. 14 indexed citations

20.

Lamont, Alan, et al.. (1988). Suppression of an established DTH response to ovalbumin in mice by feeding antigen after immunization.. PubMed Central. 64(1). 135–9. 32 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact